Accumulation of γ‐globin mRNA in human erythroid cells treated with angelicin

The aim of the present study was to determine whether angelicin is able to increase the expression of γ‐globin genes in human erythroid cells. Angelicin is structurally related to psoralens, a well‐known chemical class of photosensitizers used for their antiproliferative activity in treatment of different skin diseases (i.e., psoriasis and vitiligo). To verify the activity of angelicin, we employed two experimental cell systems, the human leukemic K562 cell line and the two‐phase liquid culture of human erythroid progenitors isolated from normal donors. The results of our investigation suggest that angelicin, compared with cytosine arabinoside, mithramycin and cisplatin, is a powerful inducer of erythroid differentiation and γ‐globin mRNA accumulation of human leukemia K562 cells. In addition, when normal human erythroid precursors were cultured in the presence of angelicin, increases of γ‐globin mRNA accumulation and fetal hemoglobin (HbF) production, even higher than those obtained using hydroxyurea, were detected. These results could have practical relevance, as pharmacologically‐mediated regulation of the expression of human γ‐globin genes, leading to HbF induction, is considered a potential therapeutic approach in hematological disorders, including β‐thalassemia and sickle cell anemia.

[1]  D. Faller,et al.  A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.

[2]  A. Riggs,et al.  Mapping psoralen cross-links at the nucleotide level in mammalian cells: suppression of cross-linking at transcription factor- or nucleosome-binding sites. , 2001, Biochemistry.

[3]  W. Filippelli,et al.  Synthesis of angelicin heteroanalogues: preliminary photobiological and pharmacological studies. , 1998, Farmaco.

[4]  G. Rodgers,et al.  NOVEL TREATMENT OPTIONS IN THE SEVERE β‐GLOBIN DISORDERS , 1995, British journal of haematology.

[5]  A. Nienhuis,et al.  Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. , 1993, The New England journal of medicine.

[6]  E. Uriarte,et al.  Synthesis and photobiological activity of new methylpsoralen derivatives. , 1992, Journal of photochemistry and photobiology. B, Biology.

[7]  R. Gambari,et al.  The DNA‐binding drugs mithramycin and chromomycin are powerful inducers of erythroid differentiation of human K562 cells , 1999, British journal of haematology.

[8]  J. Rochette,et al.  Fetal hemoglobin levels in adults. , 1994, Blood reviews.

[9]  M L Terrin,et al.  Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. , 1997, Blood.

[10]  M. Conconi,et al.  Antiproliferative activity and phototoxicity of some methyl derivatives of 5-methoxypsoralen and 5-methoxyangelicin. , 1998, Pharmacology & toxicology.

[11]  R. Micetich,et al.  Synthesis and antifungal activity of coumarins and angular furanocoumarins. , 1999, Bioorganic & medicinal chemistry.

[12]  K. Chin,et al.  Two‐phase liquid culture system models normal human adult erythropoiesis at the molecular level , 2000, European journal of haematology.

[13]  A. Oppenheim,et al.  Proliferation and maturation of human erythroid progenitors in liquid culture. , 1989, Blood.

[14]  George J. Dover,et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments] , 1992 .

[15]  A. Schechter,et al.  Diagnosis of thalassemia using cDNA amplification of circulating erythroid cell mRNA with the polymerase chain reaction. , 1992, Blood.

[16]  R Gambari,et al.  Induction of erythroid differentiation of human K562 cells by cisplatin analogs. , 2000, Biochemical pharmacology.

[17]  N. Olivieri,et al.  Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. , 1995, The New England journal of medicine.

[18]  D. Samid,et al.  Enhanced fetal hemoglobin production by phenylacetate and 4- phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia , 1993 .

[19]  P. Fossa,et al.  Activity of 3-carbethoxyangelicin photolysis products. , 1997, Journal of photochemistry and photobiology. B, Biology.

[20]  M Borgatti,et al.  Accumulation of γ‐globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine , 2001, British journal of haematology.

[21]  Richard D Moore,et al.  Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. , 1992, Blood.

[22]  C. Marzano,et al.  Photobiological Properties of 1′‐Thieno‐4,6,4′‐trimethylangelicin , 1998, Photochemistry and photobiology.

[23]  A. Schechter,et al.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.

[24]  F. Dall'acqua,et al.  Angelicins, angular analogs of psoralens: chemistry, photochemical, photobiological and phototherapeutic properties. , 1991, Pharmacology & therapeutics.

[25]  J. Clegg,et al.  K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin , 1979, Nature.

[26]  F. Dall'acqua,et al.  6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis. , 1984, Journal of medicinal chemistry.

[27]  D. Samid,et al.  Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. , 1993, Blood.

[28]  R. A. Swank,et al.  Fetal gene reactivation. , 1998, Current opinion in genetics & development.

[29]  S. Moro,et al.  New benzoquinolizin-5-one derivatives as furocoumarin analogs: DNA-interactions and molecular modeling studies. , 1999, Farmaco.

[30]  R. Gambari,et al.  Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine. , 1984, Cell differentiation.

[31]  A. Schechter,et al.  Diagnosis of thalassemia using cDNA amplification of circulating erythroid cell mRNA with the polymerase chain reaction. , 1991, Blood.

[32]  G. Stamatoyannopoulos,et al.  Cooperative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea. , 1988, Blood.

[33]  C. Marzano,et al.  Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens. , 1999, Journal of medicinal chemistry.

[34]  A. Schechter,et al.  Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. , 1993, Blood.

[35]  J. Parrish.  Phototherapy and photochemotherapy of skin diseases. , 1981, The Journal of investigative dermatology.

[36]  G. Brittenham,et al.  Elimination of Transfusions Through Induction of Fetal Hemoglobin Synthesis in Cooley's Anemia a , 1998, Annals of the New York Academy of Sciences.

[37]  A. Nienhuis,et al.  Treatment with Azacitidine of Patients with End-Stage β-Thalassemia , 1993 .

[38]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[39]  E. Fibach,et al.  The two‐step liquid culture: A novel procedure for studying maturation of human normal and pathological erythroid precursors , 1993, Stem cells.

[40]  A. Schechter,et al.  Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. , 1993, The New England journal of medicine.